Full Fed. Circ. Urged To Rehear 'Blocking Patents' Ruling
Acorda Therapeutics Inc. urged the full Federal Circuit on Wednesday to reconsider an earlier ruling invalidating several patents covering its flagship multiple sclerosis drug Ampyra, arguing that the decision "radically expands"...To view the full article, register now.
Already a subscriber? Click here to view full article